Satoshi Yoshihara

ORCID: 0000-0002-8537-2422
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma Research and Treatments
  • Immune Cell Function and Interaction
  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology
  • Cytomegalovirus and herpesvirus research
  • Polyomavirus and related diseases
  • Peptidase Inhibition and Analysis
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Protein Degradation and Inhibitors
  • Renal Transplantation Outcomes and Treatments
  • Mesenchymal stem cell research
  • Immunotherapy and Immune Responses
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Neutropenia and Cancer Infections
  • Renal and related cancers
  • Transplantation: Methods and Outcomes
  • Blood disorders and treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Neurological Complications and Syndromes
  • Immunodeficiency and Autoimmune Disorders
  • Hip disorders and treatments

Hyogo University
2022-2025

Hyogo Medical University
2015-2024

Tohoku University Hospital
2023

Keio University
2023

Kobe University Hospital
2023

The University of Tokyo
2023

Saitama Medical University
2023

Japanese Society for Dialysis Therapy
2023

Columbia University
2015-2019

Hudson Institute
2018

The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, the protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies. Here, we report outcome a phase I clinical study peptide-based patients with breast or lung cancer, myelodysplastic syndrome, acute myeloid leukemia. Patients were intradermally injected HLA-A*2402-restricted, natural, modified 9-mer peptide emulsified Montanide ISA51 adjuvant at 0.3, 1.0, 3.0...

10.1073/pnas.0405884101 article EN Proceedings of the National Academy of Sciences 2004-09-13

IntroductionWe previously reported an interim analysis of the DADI (dasatinib discontinuation) trial. The results showed that 48% patients with chronic myeloid leukemia in phase who maintained a deep molecular response (DMR) for ≥ 1 year could discontinue second- or subsequent-line dasatinib treatment safely at median follow-up 20 months. However, from longer periods would be much more useful clinical perspective.Patients and MethodsThe trial was prospective, multicenter conducted Japan....

10.1016/j.clml.2018.03.004 article EN cc-by-nc-nd Clinical Lymphoma Myeloma & Leukemia 2018-03-18

Abstract Blast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML). Although additional genetic alterations play a central role BC, the landscape and prognostic impact of these remain elusive. Here, we comprehensively investigate abnormalities 136 BC 148 phase (CP) samples obtained from 216 CML using exome targeted sequencing. One or more are found 126 (92.6%) out patients, including RUNX1 - ETS2 fusion NBEAL2 mutations. The number increase during transition...

10.1038/s41467-021-23097-w article EN cc-by Nature Communications 2021-05-14

Summary For successful chimeric antigen receptor T (CAR‐T) cell therapy, CAR‐T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B‐cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical between 30 cases that failed (7.4%) those succeeded ( n = 378). Among the failures, proportion of...

10.1111/bjh.18831 article EN cc-by-nc British Journal of Haematology 2023-04-25

The major problems in human leukocyte antigen (HLA)-mismatched stem cell transplantation (SCT) are graft failure and graft-versus-host disease (GVHD). Less-intensive regimens should be associated with a lower release of inflammatory cytokines possibly less GVHD. objective this study was to investigate whether HLA-haploidentical SCT can performed using nonmyeloablative conditioning pharmacologic GVHD prophylaxis, including glucocorticoids. Using consisting fludarabine, busulfan,...

10.1016/j.bbmt.2006.06.007 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2006-10-01

This prospective, multicenter phase I/II study of unmanipulated HLA-haploidentical reduced-intensity stem cell transplantation using a low dose anti-T lymphocyte globulin (ATG) and steroid was conducted in 5 institutions Japan. Thirty-four patients with hematologic malignancies who were an advanced stage or at high risk relapse the time enrolled. Among them, 7 underwent as second because after previous allogeneic transplantation. The conditioning regimen consisted fludarabine, busulfan, ATG...

10.1016/j.bbmt.2015.04.012 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2015-04-25

Hemophagocytic lymphohistiocytosis (HLH) has recently been increasingly reported as an important complication after stem cell transplantation, in line with the increase number of HLA-mismatched transplantation. Although previous clinical studies have shown elevation inflammatory cytokines patients HLH hematopoietic well those viral infection or autoimmune disease, disease pathogenesis remains poorly understood. Here we explored this issue humanized mice functional human lymphohematopoietic...

10.3389/fimmu.2019.00186 article EN cc-by Frontiers in Immunology 2019-02-13

Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)–based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by mAb recognizes a ubiquitously present protein, CD98 heavy chain (hc) (also known as SLC3A2). We screened more than 10,000 clones raised against MM cells and identified R8H283, bound but not normal hematopoietic or nonhematopoietic cells. R8H283 recognized CD98hc. did...

10.1126/scitranslmed.aax7706 article EN Science Translational Medicine 2022-02-16

Background. The introduction of posttransplant cyclophosphamide (PTCy) for prophylaxis against graft-versus-host disease (GVHD) has led to an increase in the number transplants from haploidentical donors. Accordingly, we aimed understand impact HLA epitope mismatch on outcomes hematopoietic stem cell transplantation (HSCT) with GVHD. Methods. This retrospective study included 1037 patients who underwent their first HSCT hematologic malignancies peripheral blood donors a Japanese registry...

10.1097/tp.0000000000005347 article EN Transplantation 2025-02-14

Abstract Objective The aim of this study was to examine gender differences in quality life (QOL), physical function and psychological status before the early phase after allogeneic haematopoietic stem cell transplantation (allo‐HSCT). Methods One hundred patients (66 men, 34 women) who underwent allo‐HSCT between July 2007 June 2011 at Hyogo College Medicine Hospital were included study. Patients evaluated for health‐related QOL using Medical Outcome Study 36‐item Short Form Health Survey;...

10.1002/pon.3128 article EN Psycho-Oncology 2012-06-27

Sam68, a nuclear RNA binding protein, binds to Src and is phosphorylated at tyrosine residues in an M-phase specific manner. Here we identified stretch of 24 amino acid the COOH-terminal portion Sam68 which function as localization signal. This signal sequence bears no apparent homology any other known sequence. However, this was found contain motif, PPXXR (P, Pro; R, Arg), conserved various proteins including hnRNP proteins. Replacement Arg motif with Ala abolished accumulation GFP fusion...

10.1016/s0014-5793(97)00455-9 article EN FEBS Letters 1997-06-09

Abstract The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer protein a antigen for these malignancies. In phase I clinical trials peptide‐based immunotherapy, two patients with advanced were intradermally injected 0.3 mg an HLA‐A*2402‐restricted, 9‐mer peptide emulsified Montanide ISA51 adjuvant. Consecutive vaccination at 2‐week intervals resulted reduction markers such as chorio‐embryonic (CEA) sialyl Lewis (x) (SLX) by transient...

10.1111/j.1348-0421.2004.tb03503.x article EN Microbiology and Immunology 2004-03-01
Coming Soon ...